Exicure Inc., a pharmaceutical company specializing in gene regulatory and immunotherapeutic drugs, has uplisted to the Nasdaq Capital Market.
The Skokie, Ill.-based company began trading under the symbol XCUR on July 31.
Exicure also priced a previously announced underwritten public offering of 27,500,000 shares at $2 apiece, with a goal of raising $55 million. The underwriters of the offer have a 30-day option to buy an additional 4,125,000 common shares. The offering is set to close on Aug. 2.
Proceeds from the offering will be used to advance immuno-oncology therapy AST-008 in a phase 1b/2 clinical trial and to develop a Spherical Nucleic Acid, or SNA, therapeutic candidate in a neurology condition. Remaining proceeds will be used for general corporate purposes.
Guggenheim Securities is sole book-running manager for the offering, while Chardan is acting as lead manager. H.C. Wainwright & Co. and Ladenburg Thalmann are co-managers for the offering.